Key Highlights

  • TVRD shares rose approximately 54% in trading today to $3.09, up from a prior close of $2.01.
  • Phase 1 results confirmed TTI-109 rapidly converts to its parent compound with equivalent exposure and improved tolerability.
  • Pharmacodynamic data showed reductions of up to 60% in disease-relevant STAT3-driven immune cell populations.
  • The company plans to advance TTI-109 into dermatologic and gastrointestinal disease programs, subject to funding and regulatory clearance.

Prodrug Design Validated Across All Study Objectives

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) shares surged in trading today after the company announced Phase 1 results for TTI-109, its next-generation STAT3 inhibitor designed as a phosphate prodrug of its earlier compound, TTI-101. Tvardi is a Houston, Texas-based clinical-stage biopharmaceutical company developing oral small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases.

The three-part study confirmed that TTI-109 rapidly converted to TTI-101 within two hours and produced nearly identical plasma levels at molar-equivalent doses, validating the company's prodrug strategy. Twenty-one day repeat dosing showed stable, dose-proportional pharmacokinetics with exposures above the STAT3 inhibitory threshold, while an exploratory pharmacodynamic analysis showed reductions of up to 60% across disease-relevant immune cell populations including Th17, T follicular helper, and B cell subsets.

Improved Tolerability Supports Broader Development Plans

Compared with TTI-101 at near-equivalent doses, TTI-109 showed substantially shorter diarrhea event duration, averaging 0.46 days versus 3.35 days, while remaining similar in duration to placebo. Based on these results, the company plans to advance TTI-109 into dermatologic and gastrointestinal disease programs, where STAT3-driven biology converges across cytokine, growth factor, and immune cell pathways, subject to clearance of an Investigational New Drug application and availability of additional funding.

Tvardi carries a market capitalization of approximately $28.99 million following today's gain, with shares trading within a 52-week range of $1.50 to $43.65. The company is also conducting a separate Phase 1b/2 trial of its earlier compound, TTI-101, in hepatocellular carcinoma.

Conclusion

Today's sharp gain reflects strong investor reception to data validating Tvardi's prodrug strategy across every stated objective, opening a potential path into new therapeutic areas with an improved tolerability profile. Investors will likely watch for progress toward IND clearance and funding needed to initiate the planned dermatologic and gastrointestinal disease programs.

FAQs

This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.